Saikal Shamkeeva

Ms. Saikal Shamkeeva

Leipzig University, Leipzig, Saxony, Germany
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AAAyazhan Akhatova
Ayazhan Akhatova
Azliyati AzizanAzliyati Azizan
Azliyati Azizan
KAKuralay Atageldiyeva
Kuralay Atageldiyeva
AAAiymkul Ashimkhanova
Aiymkul Ashimkhanova
AMAizada Marat
Aizada Marat
Gulzhanat AimagambetovaGulzhanat Aimagambetova
Gulzhanat Aimagambetova
Immunization is the most successful method in preventing and controlling infectious diseases, which has helped saving millions of lives worldwide. The discovery of the human papillomavirus (HPV) infection being associated with a variety of benign conditions and cancers has driven the development of prophylactic HPV vaccines. Currently, four HPV vaccines are available on the pharmaceutical market: Cervarix, Gardasil, Gardasil-9, and the recently developed Cecolin. Multiple studies have proven the HPV vaccines’ safety and efficacy in preventing HPV-related diseases. Since 2006, when the first HPV vaccine was approved, more than 100 World Health Organization member countries reported the implementation of HPV immunization. However, HPV vaccination dread, concerns about its safety, and associated adverse outcomes have a significant impact on the HPV vaccine implementation campaigns all over the world. Many developed countries have successfully implemented HPV immunization and achieved tremendous progress in preventing HPV-related conditions. However, there are still many countries worldwide which have not created, or have not yet implemented, HPV vaccination campaigns, or have failed due to deficient realization plans associated with establishing successful HPV vaccination programs. Lack of proper HPV information campaigns, negative media reflection, and numerous myths and fake information have led to HPV vaccine rejection in many states. Thus, context-specific health educational interventions on HPV vaccination safety, effectiveness, and benefits are important to increase the vaccines’ acceptance for efficacious prevention of HPV-associated conditions.

22 March 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MRMadlen Reinicke
Madlen Reinicke
SSSaikal Shamkeeva
Saikal Shamkeeva
MHMax Hell
Max Hell
BIBerend Isermann
Berend Isermann
Uta CeglarekUta Ceglarek
Uta Ceglarek
MHMitja L. Heinemann
Mitja L. Heinemann
Lipids are increasingly recognized as bioactive mediators of extracellular vesicle (EV) functions. However, while EV proteins and nucleic acids are well described, EV lipids are insufficiently understood due to lack of adequate quantitative methods. We adapted an established targeted and quantitative mass spectrometry (LC-MS/MS) method originally developed for analysis of 94 eicosanoids and seven polyunsaturated fatty acids (PUFA) in human plasma. Additionally, the influence of freeze–thaw (FT) cycles, injection volume, and extraction solvent were investigated. The modified protocol was applied to lipidomic analysis of differently polarized macrophage-derived EVs. We successfully quantified three PUFAs and eight eicosanoids within EVs. Lipid extraction showed reproducible PUFA and eicosanoid patterns. We found a particularly high impact of FT cycles on EV lipid profiles, with significant reductions of up to 70%. Thus, repeated FT will markedly influence analytical results and may alter EV functions, emphasizing the importance of a standardized sample pretreatment protocol for the analysis of bioactive lipids in EVs. EV lipid profiles differed largely depending on the polarization of the originating macrophages. Particularly, we observed major changes in the arachidonic acid pathway. We emphasize the importance of a standardized sample pretreatment protocol for the analysis of bioactive lipids in EVs.

11 September 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
KSKunal Kumar Singh
Kunal Kumar Singh
AGAnubhuti Gupta
Anubhuti Gupta
DFDésirée Forstner
Désirée Forstner
JGJacqueline Guettler
Jacqueline Guettler
MAMirjam Susanne Ahrens
Mirjam Susanne Ahrens
SKShrey Kohli
Shrey Kohli
Low molecular weight heparins (LMWH) are used to prevent or treat thromboembolic events during pregnancy. Although studies suggest an overall protective effect of LMWH in preeclampsia (PE), their use in PE remains controversial. LMWH may convey beneficial effects in PE independent of their anticoagulant activity, possibly by inhibiting inflammation. Here, we evaluated whether LMWH inhibit placental thromboinflammation and trophoblast NLRP3 inflammasome activation. Using an established procoagulant extracellular vesicle–induced and platelet-dependent PE-like mouse model, we show that LMWH reduces pregnancy loss and trophoblast inflammasome activation, restores altered trophoblast differentiation, and improves trophoblast proliferation in vivo and in vitro. Moreover, LMWH inhibits platelet-independent trophoblast NLRP3 (NLR family pyrin domain containing 3) inflammasome activation. Mechanistically, LMWH activates via heparin-binding epidermal growth factor (HBEGF) signaling the PI3-kinase-AKT pathway in trophoblasts, thus preventing inflammasome activation. In human PE placental explants, inflammasome activation and PI3-kinase-AKT signaling events were reduced with LMWH treatment compared with those without LMWH treatment. Thus, LMWH inhibits sterile inflammation via the HBEGF signaling pathway in trophoblasts and ameliorates PE-associated complications. These findings suggest that drugs targeting the inflammasome may be evaluated in PE and identify a signaling mechanism through which LMWH ameliorates PE, thus providing a rationale for the use of LMWH in PE.

14 December 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
INIvonne Nel
Ivonne Nel
CMCarolin Münch
Carolin Münch
SSSaikal Shamkeeva
Saikal Shamkeeva
MHMitja L. Heinemann
Mitja L. Heinemann
BIBerend Isermann
Berend Isermann
BABahriye Aktas
Bahriye Aktas
Background: The “Liquid Biopsy” has become a powerful tool for cancer research during the last decade. Circulating cell-free DNA (cfDNA) that originates from tumors has emerged as one of the most promising analytes. In contrast to plasma-derived cfDNA, only a few studies have investigated urinary cfDNA. One reason might be rapid degradation and hence inadequate concentrations for downstream analysis. In this study, we examined the stability of cfDNA in urine using different methods of preservation under various storage conditions. Methodology: To mimic patient samples, a pool of healthy male and female urine donors was spiked with a synthetic cfDNA reference standard (fragment size 170 bp) containing the T790M mutation in the EGFR gene. Spiked samples were preserved with three different buffers and with no buffer over four different storage periods (0 h; 4 h; 12 h; 24 h) at room temperature vs. 4 °C. The preservatives used were Urinary Analyte Stabilizer (UAS, Novosanis, Wijnegem, Belgium), Urine Conditioning Buffer (UCB, Zymo, Freiburg, Germany) and a self-prepared buffer called “AlloU”. CfDNA was extracted using the QIAamp MinElute ccfDNA Mini Kit (Qiagen, Hilden, Germany). CfDNA concentration was measured using the Qubit™ 4 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). Droplet digital PCR (ddPCR) was used for detection and quantification of the T790M mutation. Results: Almost no spiked cfDNA was recoverable from samples with no preservation buffer and the T790M variant was not detectable in these samples. These findings indicate that cfDNA was degraded below the detection limit by urinary nucleases. Stabilizing buffers showed varying efficiency in preventing this degradation. The most effective stabilizing buffer under all storage conditions was the UAS, enabling adequate recovery of the T790M variant using ddPCR. Conclusion: From a technical point of view, stabilizing buffers and adequate storage conditions are a prerequisite for translation of urinary cfDNA diagnostics into clinical routine.

1 October 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
SSSaikal Shamkeeva
Saikal Shamkeeva
SASaira Ambreen
Saira Ambreen
SJShihai Jiang
Shihai Jiang
MRMadlen Reinicke
Madlen Reinicke
ZLZhiyang Li
Zhiyang Li
MHMitja L. Heinemann
Mitja L. Heinemann
BACKGROUND: Extracellular vesicles (EVs) moderate a variety of physiological and pathological processes by enabling the intercellular transfer of proteins, nucleic acids, and lipids. Bioactive lipids such as polyunsaturated fatty acids or eicosanoids play an important role in propagation and resolution of inflammation and in vascular regulation. We previously found that the lipid composition of macrophage-derived EVs depends on polarization of the originating macrophages. METHODS: In this study, we investigated the role of EV-contained 12-LOX (12-lipoxygenase) metabolites in the moderation of inflammation. We used in vitro functional cell culture models as well as an in vivo sterile peritonitis model with male wild-type mice. RESULTS: We found increased levels of these 12-LOX products in M1 macrophages and M1 macrophage-derived EVs. Inhibition of 12-LOX led to significantly lower levels of 12-LOX metabolites in M1 EVs and attenuated M1 EV-mediated proinflammatory effects such as production of MCP-1 (monocyte chemoattractant protein 1) and CXCL10 (C-X-C motif chemokine ligand 10). M1 EVs induced monocyte adhesion and migration, which were also reduced by 12-LOX inhibition. In a sterile peritonitis model, M1 EVs increased the migration of monocytes into the peritoneum and the presence of macrophages in the peritoneal wall. Both effects were diminished by 12-LOX inhibition. CONCLUSIONS: Our results show that the specific lipid profile in macrophage-derived EVs is functionally relevant during inflammation. We demonstrate that eicosanoids in M1 macrophage-derived EVs educate other cells towards a proinflammatory phenotype, promoting inflammation and endothelial dysfunction.